{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.51","value":"2.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"114"}],"units":"Participants"}],"title":"Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.95","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"109"}],"units":"Participants"}],"title":"Month 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.45","value":"-2.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"86"}],"units":"Participants"}],"title":"Month 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.16","value":"-4.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"75"}],"units":"Participants"}],"title":"Month 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.28","value":"-6.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"}],"units":"Participants"}],"title":"Month 9"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.87","value":"-4.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"}],"units":"Participants"}],"title":"Month 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.96","value":"-3.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"title":"Month 18"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.98","value":"-3.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"title":"Month 24"}],"denoms":[{"counts":[{"groupId":"OG000","value":"126"}],"units":"Participants"}],"description":"Mean change from baseline on the EORTC QLQ-MY20\n\nThe EORTC has developed a myeloma module referred to as QLQ- MY20, to be administered alongside the core QLQ-C30. The QLQ-MY20 is a 20-item myeloma module intended for use among patients varying in disease stage and treatment modality.\n\nAll items will be scored from 0 to 100. The average of the scores will represent the symptoms score. A high score for a symptom scale/item represents a high level of symptomatic problem.","dispersionType":"Standard Deviation","groups":[{"description":"BB2121","id":"OG000","title":"BB2121"}],"paramType":"MEAN","populationDescription":"PRO Analysis Set","reportingStatus":"POSTED","timeFrame":"At Day 1 and at specific time points up to month 24","title":"Mean Change From Baseline on the EORTC QLQ-MY20 - Side Effects","type":"SECONDARY","unitOfMeasure":"Score on a Scale"}